UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (6), p.1133-1138

2016

Volltextzugriff (PDF)

Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema

The Journal of clinical investigation, 2000-11, Vol.106 (9), p.1081-1093

2000

Volltextzugriff (PDF)

Developmental Plasticity of CNS Microglia

Proceedings of the National Academy of Sciences - PNAS, 2001-05, Vol.98 (11), p.6295-6300

2001

Volltextzugriff (PDF)

FRI0178 Estimated Medical Expenditures among Patients with Rheumatoid Arthritis Undergoing Treatment with Tofacitinib, an Oral Janus Kinase Inhibitor

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.446-446

2014

Volltextzugriff (PDF)

THU0145 Association of Mean Changes in Laboratory Safety Parameters with C-Reactive Protein at Baseline and Week 12 in Rheumatoid Arthritis Patients Treated with Tofacitinib

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.229-229

2014

Volltextzugriff (PDF)

THU0147 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Programme

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.230-230

2014

Volltextzugriff (PDF)

THU0148 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies in Japanese Patients across the Rheumatoid Arthritis Clinical Programme

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.230-231

2014

Volltextzugriff (PDF)

Interferon gamma induction of pulmonary emphysema in the adult murine lung

The Journal of experimental medicine, 2000-12, Vol.192 (11), p.1587-1600

2000

Volltextzugriff (PDF)

AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.680-680

2013

Volltextzugriff (PDF)

THU0252 Relationship between Lymphocyte Count and Risk of Infection in Rheumatoid Arthritis Patients Treated with Tofacitinib

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A250-A251

2013

Volltextzugriff (PDF)

Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes

The European respiratory journal, 2008-07, Vol.32 (1), p.180-188

2008

Volltextzugriff (PDF)

Cathepsins and compartmentalization in antigen presentation

Current opinion in immunology, 2000-02, Vol.12 (1), p.107-113

2000

Volltextzugriff (PDF)

AB0160 Effects of TOFACITINIB (CP-690,550) on lipid biomarkers in rat adjuvant-induced arthritis (AIA) model and in patients with active rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.646-646

2013

Volltextzugriff (PDF)

AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690,550)

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.672-672

2013

Volltextzugriff (PDF)

THU0241 Haemoglobin Changes and Relationship between Anaemia and Fatigue or Vitality in Rheumatoid Arthritis Patients Treated with Tofacitinib

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A246-A247

2013

Volltextzugriff (PDF)

THU0238 Tofacitinib, an Oral Janus Kinase Inhibitor: Safety Comparison in Patients with Rheumatoid Arthritis and an Inadequate Response to Nonbiologic or Biologic Disease-Modifying Anti-Rheumatic Drugs

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A245-A245

2013

Volltextzugriff (PDF)

FRI0137 Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A416-A416

2013

Volltextzugriff (PDF)

OP0154 Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with A Cumulative Exposure of 12,664 Patient-Years

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.119-120

2014

Volltextzugriff (PDF)

Emerging roles for cysteine proteases in human biology

Annual review of physiology, 1997-01, Vol.59 (1), p.63-88

1997

Volltextzugriff (PDF)

THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A242-A242

2013

Volltextzugriff (PDF)

THU0140 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical programme

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.202-203

2013

Volltextzugriff (PDF)

THU0131 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical programme

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.199-199

2013

Volltextzugriff (PDF)

OP0163 Evaluation of Influenza and Pneumococcal Vaccine Responses in Rheumatoid Arthritis Patients Using Tofacitinib

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A107-A108

2013

Volltextzugriff (PDF)

THU0136 Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral jak inhibitor

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.201-201

2013

Volltextzugriff (PDF)

Development of a business model resilience framework for managers and strategic decision-makers

Schmalenbachs Zeitschrift für betriebswirtschaftliche Forschung, 2022, Vol.74 (4), p.575-601

2022

Volltextzugriff (PDF)

1 – 25 von 469

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(410)
Mit Volltextzugriff
(410)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(272)
Life Sciences & Biomedicine
(177)
Physical Sciences
(123)
Humans
(105)
Meteorology & Atmospheric Sciences
(100)
Biological And Medical Sciences
(60)
Technology
(55)
Animals
(52)
Male
(52)
Geology
(50)
Geosciences, Multidisciplinary
(48)
Engineering
(47)
Female
(44)
Astronomy & Astrophysics
(43)
Engineering, Aerospace
(43)
Medical Sciences
(40)
Environmental Sciences
(36)
Environmental Sciences & Ecology
(35)
Mice
(31)
Middle Aged
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema

Developmental Plasticity of CNS Microglia

FRI0178 Estimated Medical Expenditures among Patients with Rheumatoid Arthritis Undergoing Treatment with Tofacitinib, an Oral Janus Kinase Inhibitor

THU0145 Association of Mean Changes in Laboratory Safety Parameters with C-Reactive Protein at Baseline and Week 12 in Rheumatoid Arthritis Patients Treated with Tofacitinib

THU0147 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Programme

THU0148 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies in Japanese Patients across the Rheumatoid Arthritis Clinical Programme

Interferon gamma induction of pulmonary emphysema in the adult murine lung

AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects

THU0252 Relationship between Lymphocyte Count and Risk of Infection in Rheumatoid Arthritis Patients Treated with Tofacitinib

Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes

Cathepsins and compartmentalization in antigen presentation

AB0160 Effects of TOFACITINIB (CP-690,550) on lipid biomarkers in rat adjuvant-induced arthritis (AIA) model and in patients with active rheumatoid arthritis

AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690,550)

THU0241 Haemoglobin Changes and Relationship between Anaemia and Fatigue or Vitality in Rheumatoid Arthritis Patients Treated with Tofacitinib

THU0238 Tofacitinib, an Oral Janus Kinase Inhibitor: Safety Comparison in Patients with Rheumatoid Arthritis and an Inadequate Response to Nonbiologic or Biologic Disease-Modifying Anti-Rheumatic Drugs

FRI0137 Effects of tofacitinib on lipid biomarkers in patients with active rheumatoid arthritis

OP0154 Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with A Cumulative Exposure of 12,664 Patient-Years

Emerging roles for cysteine proteases in human biology

THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population

THU0140 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical programme

THU0131 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical programme

OP0163 Evaluation of Influenza and Pneumococcal Vaccine Responses in Rheumatoid Arthritis Patients Using Tofacitinib

THU0136 Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel, oral jak inhibitor

Development of a business model resilience framework for managers and strategic decision-makers

Suchergebnisse filtern